What Is Pfizer (PFE) Really Gaining From Its Sec61 Drug Discovery Deal? Bailey Pemberton Tue, October 13, 2026 at 3:15 PM EDT 3 min read PFE -0.12% GC=F -0.05% Trade Pfizer on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small molecule drugs.
Enodia grants Pfizer access to its proprietary Sec61 inhibitor platform, while Pfizer takes charge of clinical, regulatory, and commercial development.
The partnership is structured to apply Sec61-directed molecules across multiple disease areas, adding a new discovery track to Pfizer's pipeline.
This new Sec61-focused collaboration with Enodia deserves to be weighed against the rest of our Pfizer analysis. We have also spotted 4 warning signs worth knowing about at Pfizer.
Drug discovery tied to targets like Sec61 is attracting wider interest, and this Pfizer move is only one way to get exposure, so it can be worth comparing it with peers at 36 elite gold producer stocks.
Pfizer is a US-based pharmaceuticals group that discovers, develops, manufactures, and sells biopharmaceutical products worldwide. A partnership targeting Sec61 slots directly into its focus on new small molecule therapies across multiple disease areas. For readers, this frames the Enodia agreement as one more attempt to broaden Pfizer's research pipeline rather than a standalone bet.
2 things going right for Pfizer that this headline doesn't cover.
This Enodia deal leans into the Pfizer Narrative that launched and acquired therapies need to take more weight as COVID revenue steps down. Sec61 inhibitors offer another way to widen the small molecule portfolio across oncology and other diseases, which lines up with the catalyst around expanding launched and acquired products that management already pegs at about a US$13b annualized run rate. The structure of the agreement, with Enodia focused on discovery and Pfizer handling trials and commercialization later, also fits the push to use partnerships and internal scale together rather than building every platform alone.
See how these catalysts shape Pfizer's path to a $28.88 fair value.
The clearest early proof point to watch is whether any Sec61 candidate actually moves out of discovery and into a named Pfizer clinical program with a disclosed target and trial design. A first Phase 1 filing or patient dosing update tied to this collaboration would be a concrete sign that Enodia's platform is translating into assets that can matter for Pfizer's pipeline, rather than remaining a long dated option.
Add Pfizer to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
